@article{oai:soar-ir.repo.nii.ac.jp:00019350, author = {Shimodaira, S and Higuchi, Y and Koya, T and Kobayashi, T and Yanagisawa, R and Hirabayashi, K and Ito, K and Koizumi, T and Maejima, S and Udagawa, N}, issue = {1}, journal = {Pharmaceutical Regulatory Affairs}, month = {Feb}, note = {Background: Dendritic cell (DC)-based vaccination is considered to be a potentially effective therapeutic strategy against advanced cancer. The aim of this study was to address the smoking history that might affect the preparation of DC vaccines in validated instructional manufacture. Materials and Methods: Data on mature DCs generated from 102 sessions of leukapheresis performed on 92 patients with advanced cancer or sarcoma were retrospectively evaluated and compared in relation to the data between their smoking history and the generation of DCs from these patients. 61 patients with adenocarcinoma, including 7 with lung, 10 with breast, 8 with stomach, 12 with colorectal, and 23 with pancreatic adenocarcinoma were enrolled. Results: The average yield of autologous DCs (15.5 ± 8.3x107) was thought to be dependent on the number of monocytes (124.2 ± 74.1x107) collected by leukapheresis. The average ratio of DCs/apheresed monocytes (DC/aM ratio) was lower in the smoker group (11.1 ± 7.2%) than that in the non-smoker group (17.2 ± 9.3%, p=0.001). The number of DCs and the DC/aM ratio were lower in the patients with gastric and pancreatic cancer than in those with adenocarcinoma of other sites. Conclusions: As cancer therapy moves forward into the field of persona, Article, Pharmaceutical Regulatory Affairs. 4(1):133 (2015)}, title = {Smoking influences the yield of dendritic cells for cancer immunotherapy}, volume = {4}, year = {2015} }